RxDoctor Payments Data

Walter Urba

Medical Oncology · Portland, ORNPI 1548253602

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $6,232 of the $6,749 with a category attached, or 92.3%. E.r. Squibb & Sons, L.L.C. accounts for 98.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $6,612 and has fallen 98.4% since, to $104 in 2024.

$6,749in general payments, 2019–2025

Across 20 payments — averaging $337.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$7K
  • Regeneron Healthcare Solutions, Inc.$83
  • Merck$33
  • Daiichi Sankyo Inc.$20
$1,348,349in research payments, 2019–2025

Across 13 payments — averaging $103,719 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$1M
  • E.r. Squibb & Sons, L.L.C.$260K
  • Merck$41K

What the payments were for

  • Travel & lodging$6,23292%
  • Food & beverage$5188%

General payments by program year

19
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,749 in reported general payments places this provider in the 70th percentile of 92 medical oncology providers in Oregon.

See all medical oncology providers in Oregon

Other medical oncology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →